A Clinical Study to Assess the Efficacy and Safety of a Healing Ointment on Diaper Rash

NCT06015217 | Completed Phase 4 FDA Drug

• 1 other identifier: GLI.04.US.SL.027
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to assess the efficacy and safety of a Healing Ointment in infants 2-24 months with mild to moderate diaper rash. The main question it aims to answer is: • does a Healing Ointment improve skin texture and smoothness in infants with mild to moderate diaper dermatitis? Participants will use a Healing Ointment on the diaper area with every diaper change, have the Investigator perform efficacy and tolerability assessments, and complete questionnaires regarding subject satisfaction.

Conditions

Diaper Rash

Outcome Measures

Primary Outcomes (1)

• Product Efficacy

  Product efficacy will be measured by Investigator's evaluation of skin's tactile smoothness, visual skin texture, and diaper dermatitis. Skin smoothness (tactile) and skin texture will be measured on a 10-point modified Griffith's scale, where 0 is the best possible condition and 9 is the worst possible condition, and diaper dermatitis will be measured on a 5-point scale, where 0 is the best possible condition and 4 is the worst possible condition. A decrease in scores indicates an improvement.

  Week 1, Week 3

Secondary Outcomes (2)

• Subject Satisfaction

  Day 1, Week 1, Week 3

• Product Tolerability

  Week 1, Week 3

Study Arms (1)

Treatment Group

EXPERIMENTAL

All subjects have mild to moderate diaper dermatitis and are given "Cetaphil Healing Ointment" to use with every diaper change.

Drug: "Cetaphil Healing Ointment"

Interventions

"Cetaphil Healing Ointment" DRUG

Subjects will use "Cetaphil Healing Ointment" on the diaper rash area with every diaper change

Treatment Group

Eligibility Criteria

• Age: 2 Months - 24 Months
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• The subjects must meet all the following criteria to be eligible for the study:
• Infant subjects aged 2 months to 24 months
• Females and males
• All Fitzpatrick skin types I-VI
• All races and ethnicities
• Subject diagnosed with mild-to-moderate diaper rash
• Subject with healthy immune systems
• Willing to be photographed at each visit (optional)
• Willing to abstain from use of any other topical diaper rash treatments (ointments, moisturizers, emollients, creams, and wipes) other than the assigned test product and skincare products that have been routinely used on the diaper area during the duration of the study
• Willing to continue using regular brands of face/body cleanser and not to begin use of any new skincare products other than the test product for the duration of the study
• Parent/legal guardian/legal guardians must be at least 18 years old and are willing and able to present proof of legal guardianship
• Parent/legal guardian/legal guardian with ability to read, understand and give consent for participation in the study
• Parent/legal guardians/legal guardians willing to sign a photography release form
• Parent/legal guardian/guardian must agree to adhere to the procedures and requirements of the study and to report to the site on the day(s) and at the time(s) scheduled for the assessments

You may not qualify if:

• Subject diagnosed with severe diaper rash
• History of allergy or hypersensitivity to any ingredient of the test product
• Presence of any disease or lesions near or on the area to be treated, e.g.,
• Inflammation, active, or chronic infection in or near the treatment area
• Psoriasis, eczema, rosacea, atopic dermatitis, herpes zoster/herpes simplex, and acanthosis
• Scars or deformities
• History of coexisting bacterial infections or medical conditions with uncontrolled gastrointestinal diseases and/or bowel movements
• History of severe elastosis and/or excessive sun exposure that, in the opinion of the Investigator, could have affected the outcome of the study
• Planning on having surgeries and/or invasive medical procedures during the course of the study
• Treatment with chemotherapy, immunosuppressive agents, inhaled corticosteroids, immunomodulatory therapy (e.g., monoclonal antibodies or antiviral treatment for human immunodeficiency virus or hepatitis C)
• Current use of topical corticosteroids, topical prescription, or oral antibiotics in the treatment area, or use within last 2 weeks
• Current use of over-the counter topical medications for diaper rash
• History of cancer or previous radiation near or on the treatment area
• Human immunodeficiency virus positive or active hepatitis
• Presence of dermal markings on or near the treatment area that, in the opinion of the Investigator, will interfere with the clinical assessments

Sponsors & Collaborators

• Galderma R&D: lead

Study Sites (1)

Young Skin MD

Coral Springs, Florida, 33067, United States

Location

MeSH Terms

Conditions

Diaper Rash

Condition Hierarchy (Ancestors)

Dermatitis, Irritant; Dermatitis, Contact; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous

Study Officials

• Latanya Benjamin

  Young Skin

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This study only has a single group, and all subjects receive the same treatment.

Study Record Dates

• First Submitted: August 14, 2023
• First Posted: August 29, 2023
• Study Start: August 25, 2023
• Primary Completion: December 13, 2023
• Study Completion: December 13, 2023
• Last Updated: April 11, 2024

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)